Arbutus Biopharma (ABUS) Earnings Date, Estimates & Call Transcripts $3.46 -0.09 (-2.54%) (As of 12/17/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Arbutus Biopharma Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arbutus Biopharma and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataABUS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ABUS Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Arbutus Biopharma Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241-$0.17-$0.17-$0.17Q2 20241-$0.17-$0.17-$0.17Q3 20241-$0.18-$0.18-$0.18Q4 20242-$0.18-$0.09-$0.14FY 20245-$0.70-$0.61-$0.66Q2 20251-$0.10-$0.10-$0.10Q4 20251-$0.11-$0.11-$0.11 Arbutus Biopharma Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails8/1/2024Q2 2024-$0.10-$0.11 -$0.01-$0.11$1.54M$1.73M5/2/2024Q1 2024-$0.10-$0.10--$0.10$2.16M$1.53M2/29/2024Q4 2023-$0.12-$0.12--$0.12$4.74M$2.15M11/7/2023Q3 2023-$0.12-$0.12--$0.12$3.78M$4.66M8/3/2023Q2 2023-$0.12-$0.10+$0.02-$0.10$5.02M$4.65M5/4/2023Q1 2023-$0.14-$0.10+$0.04-$0.10$4.52M$6.69M Get the Latest News and Ratings for ABUS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter. 3/2/2023Q4 2022-$0.14-$0.14--$0.14$6.31M$6.25M Arbutus Biopharma Earnings - Frequently Asked Questions How much revenue does Arbutus Biopharma generate each year? Arbutus Biopharma (NASDAQ:ABUS) has a recorded annual revenue of $6.74 million. How much profit does Arbutus Biopharma generate each year? Arbutus Biopharma (NASDAQ:ABUS) has a recorded net income of -$72.85 million. ABUS has generated -$0.43 earnings per share over the last four quarters. What is Arbutus Biopharma's EPS forecast for next year? Arbutus Biopharma's earnings are expected to grow from ($0.39) per share to ($0.34) per share in the next year. More Earnings Resources from MarketBeat Related Companies DYN Earnings Results CPRX Earnings Results PTGX Earnings Results AGIO Earnings Results IOVA Earnings Results AMRX Earnings Results LBPH Earnings Results NAMS Earnings Results IDYA Earnings Results RXRX Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. This page (NASDAQ:ABUS) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arbutus Biopharma Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arbutus Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
